To Evaluate the Use of Radiomics to Classify Between Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease

To investigate the ability of machine learning models based on radiomic features extracted from thin-section CT images to differentiate IPF patients from non-IPF interstitial lung diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Lung Diseases Lung Diseases, Interstitial Pulmonary Fibrosis Respiratory Tract Diseases Usual Interstitial Pneumonia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Maastricht University

Maastricht, Limburg, 6229ER, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

UIP with final diagnosis in biopsy
ILDs with final diagnosis in biopsy

Exclusion criteria

patients with no biopsy confirmation

Treatment and study plan

radiomics

Diagnostic Test

The high-throughput extraction of large amounts of quantitative image features from medical images

Primary outcomes

IPF classifier

Time frame: Up to 30 weeks

Model based on Radiomic that can differentiate IPF from ILDs.

Sponsors and collaborators

Lead sponsor

Maastricht University

Other

Collaborators

Université Libre de Bruxelles

Registry information

Official study title

Multi-center Validation of a Radiomics Based Model for the Diagnosis of Idiopathic Pulmonary Fibrosis

Important dates

Study start: 2005
Primary completion: 2017
Study completion: 2017
First posted: Jun 12, 2020
Registry last updated: Jun 12, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed